(Q35216972)

7 August 2017

1 reference

title

Molecular targets in immune-mediated diseases: the case of tumour necrosis factor and rheumatoid arthritis (English)

1 reference

7 August 2017

0 references

1 reference

Ian K Campbell

1

1 reference

7 August 2017

Lynden J Roberts

series ordinal

2

1 reference

7 August 2017

Ian P Wicks

series ordinal

3

1 reference

7 August 2017

publication date

1 October 2003

1 reference

Immunology & Cell Biology

7 August 2017

published in

1 reference

7 August 2017

volume

81

1 reference

7 August 2017

issue

5

1 reference

7 August 2017

page(s)

354-366

1 reference

Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis?

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

The genetics revolution and the assault on rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

The role of T cells in the immunopathogenesis of rheumatoid arthritis: new perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Rheumatoid factor autoantibodies in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Evolving concepts of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Recombinant soluble human Fc gamma RII: production, characterization, and inhibition of the Arthus reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Arthritogenic monoclonal antibodies from K/BxN mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Role of cytokines in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Cytokine pathways and joint inflammation in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

How important are T cells in chronic rheumatoid synovitis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Apoptosis as a therapeutic tool in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Anti-cytokine therapy in chronic destructive arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Severe inflammatory arthritis and lymphadenopathy in the absence of TNF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

The tumor necrosis factor ligand and receptor families.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Signaling by the TNF receptor superfamily and T cell homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune re

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Characterization of tumor necrosis factor-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Distinct roles for lymphotoxin-alpha and tumor necrosis factor in organogenesis and spatial organization of lymphoid tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Prevention of diabetes in nonobese diabetic mice by tumor necrosis factor (TNF): similarities between TNF-alpha and interleukin 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Induction of apoptosis in mature T cells by tumour necrosis factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Homeostasis and self-tolerance in the immune system: turning lymphocytes off.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Collagen-induced arthritis in C57BL/6 (H-2b) mice: new insights into an important disease model of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Distinct roles for the NF-kappaB1 (p50) and c-Rel transcription factors in inflammatory arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Role of TNF alpha in the induction of antigen induced arthritis in the rabbit and the anti-arthritic effect of species specific TNF alpha neutralising monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Uncoupling of inflammatory and destructive mechanisms in arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Mast cells: a cellular link between autoantibodies and inflammatory arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Essential role of neutrophils in the initiation and progression of a murine model of rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Effect of Mycobacterium tuberculosis-specific 10-kilodalton antigen on macrophage release of tumor necrosis factor alpha and nitric oxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Tumor necrosis, cachexia, shock, and inflammation: a common mediator

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Infliximab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Effect of infliximab on sight-threatening panuveitis in Behçet's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

An endotoxin-induced serum factor that causes necrosis of tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Tumor necrosis factor in the serum of patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Adverse reactions to TNF-α inhibitors in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFalpha receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

The role of CD40 ligand and tumor necrosis factor alpha signaling in the transgenic K/BxN mouse model of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Onset of multiple sclerosis associated with anti-TNF therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

Invasive Pulmonary Aspergillosis Associated with Infliximab Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0818-9641.2003.01185.X

10.1046/J.0818-9641.2003.01185.X

21 January 2018

Identifiers

DOI

1 reference

7 August 2017

1 reference